These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 15472714)

  • 1. Replication-selective oncolytic viruses in the treatment of cancer.
    Everts B; van der Poel HG
    Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in oncolytic viral therapy.
    Woo Y; Adusumilli PS; Fong Y
    Curr Opin Investig Drugs; 2006 Jun; 7(6):549-59. PubMed ID: 16784026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer.
    Kirn D
    Oncogene; 2000 Dec; 19(56):6660-9. PubMed ID: 11426652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic viruses for the treatment of cancer: current strategies and clinical trials.
    Ries SJ; Brandts CH
    Drug Discov Today; 2004 Sep; 9(17):759-68. PubMed ID: 15450242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy.
    Oosterhoff D; van Beusechem VW
    J Exp Ther Oncol; 2004 Apr; 4(1):37-57. PubMed ID: 15255291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic adenoviruses - selective retargeting to tumor cells.
    Mathis JM; Stoff-Khalili MA; Curiel DT
    Oncogene; 2005 Nov; 24(52):7775-91. PubMed ID: 16299537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of replication-selective, oncolytic viruses for the treatment of human cancers.
    Wildner O
    Curr Opin Mol Ther; 2003 Aug; 5(4):351-61. PubMed ID: 14513677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
    Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
    J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.
    Hermiston TW; Kuhn I
    Cancer Gene Ther; 2002 Dec; 9(12):1022-35. PubMed ID: 12522441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Viral therapy of cancer].
    Suzuki K; Curiel DT
    Rev Invest Clin; 2001; 53(4):346-56. PubMed ID: 11599483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selectively replicating oncolytic adenoviruses as cancer therapeutics.
    Yu DC; Working P; Ando D
    Curr Opin Mol Ther; 2002 Oct; 4(5):435-43. PubMed ID: 12435044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oncolytic viruses for genetic therapy of gastrointestinal tumors].
    Bitzer M; Lauer UM
    Z Gastroenterol; 2003 Jul; 41(7):667-74. PubMed ID: 12858239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
    Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication-selective viruses for cancer therapy.
    Biederer C; Ries S; Brandts CH; McCormick F
    J Mol Med (Berl); 2002 Mar; 80(3):163-75. PubMed ID: 11894142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of virotherapy for effective tumor treatment.
    Garcia-Aragoncillo E; Hernandez-Alcoceba R
    Curr Opin Mol Ther; 2010 Aug; 12(4):403-11. PubMed ID: 20677091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.
    Barton KN; Paielli D; Zhang Y; Koul S; Brown SL; Lu M; Seely J; Kim JH; Freytag SO
    Mol Ther; 2006 Feb; 13(2):347-56. PubMed ID: 16290236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).
    Bauerschmitz GJ; Barker SD; Hemminki A
    Int J Oncol; 2002 Dec; 21(6):1161-74. PubMed ID: 12429964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
    Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
    Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.